ArticleClinical case reports2026
Successful Management of Fetal Supraventricular Tachycardia With Flecainide in a Case Complicated by Early Hydrops Fetalis: A Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fetal arrhythmia that can lead to hydrops fetalis and fetal heart failure if untreated. This case report describes the successful treatment of a fetus with SVT at 26 weeks of gestation using flecainide. A 37-year-old gravida 3, para 2 woman was diagnosed with fetal SVT during a routine ultrasound, which also revealed mild pleural effusion, pericardial effusion, and ascites, raising concerns for hydrops fetalis. A fetal echocardiogram confirmed a heart rate of 250-300 beats per minute with preserved cardiac function. The mother was started on oral flecainide at 100 mg twice daily, which was increased to 150 mg twice daily after 3 days due to persistent fetal tachycardia. Within 24 h of the dosage adjustment, the fetal heart rate normalized to 120-130 beats per minute, and the hydrops resolved by the third week of treatment. The mother delivered a healthy baby at 39 weeks, and the infant has remained free of SVT episodes to date. This case demonstrates the efficacy and safety of flecainide in treating fetal SVT, particularly in cases complicated by early hydrops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.